Univest
Univest
  • Markets

India Glycols Analyst Review May 2026

  • May 21, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
India Glycols

This India Glycols analyst review for May 2026 covers the key data investors need for INDIAGLYCO at its current price of Rs 978.70. India Glycols (NSE: INDIAGLYCO) is the world’s only manufacturer of bio-based mono ethylene glycol from sugarcane ethanol with a market capitalisation of approximately Rs 2,800 crore. The analyst consensus target of Rs 1,050 implies meaningful upside, and this India Glycols analyst review examines technical levels, business performance, valuation, and key risks for INDIAGLYCO through FY27.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • India Glycols Company Snapshot May 2026
  • Analyst Insight in This India Glycols Analyst Review
  • Technical Analysis in This India Glycols Analyst Review
  • Key Support and Resistance Levels
  • Business Segment Analysis
    • Bio-MEG (World’s Only Bio-Based MEG Producer)
    • Specialty Glycols (DEG, TEG for Pharma and Exports)
    • Industrial Gases and Ethanol Products
  • Valuation in This India Glycols Analyst Review
  • Trade Outlook for India Glycols
  • Key Risks for India Glycols in FY27
  • Conclusion: India Glycols Analyst Review Verdict for 2026
  • Frequently Asked Questions: India Glycols Analyst Review 2026
    • What is the analyst target for India Glycols in 2026?
    • Is India Glycols a good investment at Rs 978.70?
    • What is India Glycols’s 52-week high and low?
    • What are the key risks for India Glycols?
    • Where can I track live data for India Glycols?

India Glycols Company Snapshot May 2026

India Glycols’ bio-MEG (bio-based mono ethylene glycol) is a premium sustainable alternative to petroleum-based MEG used in PET bottles and polyester textiles. Specialty glycols, industrial gases, and ethanol-based products complete the portfolio. The table below summarises the key data referenced in this India Glycols analyst review.

Parameter Value
NSE Ticker INDIAGLYCO
Sector Specialty Chemicals – Glycols
CMP (May 2026) Rs 978.70
52 Week High Rs 1,222.00
52 Week Low Rs 792.50
Market Cap Rs 2,800 Crore
Trailing P/E 15x
Analyst Consensus Target Rs 1,050
Bull Case Target Rs 1,280
Bear Case Target Rs 690

Analyst Insight in This India Glycols Analyst Review

Senior Research Analyst Ankit Jaiswal flags India Glycols as a stock to watch in May 2026. At Rs 978.70, Ankit Jaiswal identifies key support in the Rs 808 to Rs 930 band and resistance near Rs 1037. He suggests watching India Glycols for a potential move toward Rs 1,050, subject to Specialty Chemicals – Glycols sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this India Glycols analyst review and does not constitute a trade recommendation.

Technical Analysis in This India Glycols Analyst Review

At Rs 978.70, INDIAGLYCO is trading within its 52-week band of Rs 792.50 to Rs 1,222.00. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 808 to Rs 930 band while resistance is seen in the Rs 1037 to Rs 1014 zone. A sustained move above Rs 1037 could open the path toward the analyst consensus target of Rs 1,050 as identified in this India Glycols analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

  • Support Zone: Rs 808 to Rs 930 – investors tracking this India Glycols analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for INDIAGLYCO.
  • Resistance Zone: Rs 1037 to Rs 1014 – a sustained close above Rs 1037 would be a positive breakout signal worth flagging in this India Glycols analyst review.
  • Medium-Term Target: The analyst consensus of Rs 1,050 represents the base-case upside scenario in this India Glycols analyst review.

Business Segment Analysis

Bio-MEG (World’s Only Bio-Based MEG Producer)

This is the primary revenue and margin driver for India Glycols, directly supporting the earnings trajectory toward the consensus target of Rs 1,050.

Specialty Glycols (DEG, TEG for Pharma and Exports)

This segment adds scale and diversification to India Glycols’s business model and is a meaningful EPS contributor through FY27 and FY28.

Industrial Gases and Ethanol Products

This represents the medium-term growth frontier for India Glycols and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This India Glycols Analyst Review

At Rs 978.70, India Glycols trades at a trailing P/E of 15x. This India Glycols analyst review presents three scenarios: a bull case of Rs 1,280 on strong earnings delivery, a base case of Rs 1,050 at analyst consensus, and a bear case of Rs 690 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this India Glycols analyst review.

Scenario Target Price Key Condition
Bull Case Rs 1,280 Strong earnings delivery and sector re-rating
Base Case (Consensus) Rs 1,050 Moderate growth, analyst consensus estimate
Bear Case Rs 690 Earnings miss or macro headwinds

Trade Outlook for India Glycols

Based on the technical and fundamental analysis in this India Glycols analyst review, investors might watch INDIAGLYCO near the support zone of Rs 808 to Rs 930 for potential opportunities. A flag above Rs 1037 could suggest improving momentum toward Rs 1,050. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for India Glycols in FY27

A well-rounded India Glycols analyst review must assess downside risks. Key risks for India Glycols include a macro slowdown affecting Specialty Chemicals – Glycols sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in INDIAGLYCO.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: India Glycols Analyst Review Verdict for 2026

This India Glycols analyst review concludes that at Rs 978.70, INDIAGLYCO offers a defined risk-reward with a consensus target of Rs 1,050. The 52-week range of Rs 792.50 to Rs 1,222.00 provides context on the current entry point. Use this India Glycols analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on INDIAGLYCO.

Frequently Asked Questions: India Glycols Analyst Review 2026

What is the analyst target for India Glycols in 2026?

The analyst consensus target is Rs 1,050, with a bull case of Rs 1,280 and a bear case of Rs 690. This India Glycols analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is India Glycols a good investment at Rs 978.70?

At Rs 978.70 with a P/E of 15x and a consensus target of Rs 1,050, this India Glycols analyst review is constructive for medium to long-term investors in the Specialty Chemicals – Glycols sector. Always consult a SEBI-registered advisor before investing.

What is India Glycols’s 52-week high and low?

The 52-week high is Rs 1,222.00 and the 52-week low is Rs 792.50. At Rs 978.70, INDIAGLYCO is positioned within this range as noted in this India Glycols analyst review.

What are the key risks for India Glycols?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Specialty Chemicals – Glycols sector as assessed in this India Glycols analyst review.

Where can I track live data for India Glycols?

Track India Glycols’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this India Glycols analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply